Nitroimidazole (Chagas)
objective
Generate new drug candidates for the treatment of Chagas to be assessed in clinical trials
project start
2012
project status
Completed
last phase of drug development

Drug Discovery

Translational research

Clinical trials

Registration & access
updated 31 Aug 2015
An opportunistic approach has been undertaken to assess compounds issuing from the VL-2098 back-up programme (nitroimidazooxazine series) showing activity against T. cruzi in vitro, evaluating the most promising candidates in in vivo models of Chagas disease. Two VL lead back-ups belonging to different sub-series (7-substituted nitroimidazooxazines and PA-824 analogues) are active and have been selected for further assessment against Chagas disease in the new bioluminescence in vivo model at LSHTM.
- Germany - Federal Ministry of Education and Research (BMBF) through KfW
- Switzerland - Swiss Agency for Development and Cooperation (SDC)
- The Netherlands - Dutch Ministry of Foreign Affairs (DGIS)
- UK - UK International Development
- Médecins Sans Frontières International
- Other private foundations and individuals
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.